Steroid treatment causes deterioration of myocardial function in the δ-sarcoglycan-deficient mouse model for dilated cardiomyopathy

Cardiovascular Research

Volumn 79, Issue 4, 2008, Pages 652-661

  Bauer, R ^a   MacGowan, G A ^b   Blain, A ^a   Bushby, K ^a   Straub, V ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Corticosteroids; Delta sarcogylcan; Dilated cardiomyopathy; Muscular dystrophy

Indexed keywords

ALPHA SARCOGLYCAN; DELTA SARCOGLYCAN; DOBUTAMINE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; HEART FUNCTION; HEART HEMODYNAMICS; HEART INJURY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART OUTPUT; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANIMALS; BODY WEIGHT; CARDIOMYOPATHY, DILATED; DISEASE MODELS, ANIMAL; DOBUTAMINE; FIBROSIS; HEMODYNAMICS; INFUSIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; MYOCARDIUM; PREDNISOLONE; RNA, MESSENGER; SARCOGLYCANS; STROKE VOLUME; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 52449087790     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn131     Document Type: Article

References (40)

1. Michels VV, Moll PP, Miller FA, Tajik AJ, Chu JS, Driscoll DJ et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 1992;326:77-82.
2. Heydemann A, McNally EM. Consequences of disrupting the dystrophinsarcoglycan complex in cardiac and skeletal myopathy. Trends Cardiovasc Med 2007;17:55-59.
3. Duggan DJ, Gorospe JR, Fanin M, Hoffman EP, Angelini C. Mutations in the sarcoglycan genes in patients with myopathy. N Engl J Med 1997;336:618-624.
4. Politano L, Nigro V, Passamano L, Petretta V, Comi LI, Papparella S et al. Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromuscul Disord 2001;11:178-185.
5. Tsubata S, Bowles KR, Vatta M, Zintz C, Titus J, Muhonen L et al. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest 2000;106:655-662.
6. Lapidos KA, Kakkar R, McNally EM. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 2004;94:1023-1031.
7. Danialou G, Comtois AS, Dudley R, Karpati G, Vincent G, Des Rosiers C et al. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J 2001;15:1655-1657.
8. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 2002;11:263-272.
9. Hodgetts S, Radley H, Davies M, Grounds MD. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNF alpha function with Etanercept in mdx mice. Neuromuscul Disord 2006;16:591-602.
10. Vanderheyde N, Verhasselt V, Goldman M, Willems F. Inhibition of human dendritic cell functions by methylprednisolone. Transplantation 1999;67:1342-1347.
11. Liakopoulos OJ, Teucher N, Muhlfeld C, Middel P, Heusch G, Schoendube FA et al. Prevention of TNF alpha-associated myocardial dysfunction resulting from cardiopulmonary bypass and cardioplegic arrest by glucocorticoid treatment. Eur J Cardio-thorac Surg 2006;30:263-270.
12. Bushby K, Muntoni F, Urtizberea A, Hughes R, Griggs R. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. Neuromuscul Disord 2004;14:526-534.
13. Connolly AM, Pestronk A, Mehta S, Al-Lozi M. Primary alpha-sarcoglycan deficiency responsive to immunosuppression over three years. Muscle Nerve 1998;21:1549-1553.
14. Silversides CK, Webb GD, Harris VA, Biggar DW. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 2003;91:769-772.
15. Straub V, Duclos F, Venzke DP, Lee JC, Cutshall S, Leveille CJ et al. Molecular pathogenesis of muscle degeneration in the delta-sarcoglycan-eficient hamster. Am J Pathol 1998;153:1623- 1630.
16. Coral-Vazquez R, Cohn RD, Moore SA, Hill JA, Weiss RM, Davisson RL et al. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell 1999;98:465-474.
17. Baan J, van der Velde ET, de Bruin HG, Smeenk GJ, Koops J, van Dijk AD et al. Continuous measurement of left ventricular volume in animals and humans by conductance catheter. Circulation 1984;70:812-823.
18. MacGowan GA, Rager J, Shroff SG, Mathier MA. In vivo alpha-adrenergic responses and troponin I phosphorylation: anesthesia interactions. J Appl Physiol 2005;98:1163-1170.
19. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30:e36.
20. Feldman MD, Erikson JM, Mao Y, Korcarz CE, Lang RM, Freeman GL. Validation of a mouse conductance system to determine LV volume: comparison to echocardiography and crystals. Am J Physiol Heart Circ Physiol 2000;279:H1698-H1707.
21. Steendijk P, Staal E, Jukema JW, Baan J. Hypertonic saline method accurately determines parallel conductance for dual-field conductance catheter. Am J Physiol Heart Circ Physiol 2001;281:H755-H763.
22. Little WC. The left ventricular dP/dtmax-end-diastolic volume relation in closed-chest dogs. Circ Res 1985;56:808-815.
23. Suga H, Sagawa K. Instantaneous pressure-volume relationships and their ratio in the excised, supported canine left ventricle. Circ Res 1974;35:117-126.
24. Glower DD, Spratt JA, Snow ND, Kabas JS, Davis JW, Olsen CO et al. Linearity of the Frank-Starling relationship in the intact heart: the concept of preload recruitable stroke work. Circulation 1985;71:994-1009.
25. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003;107:714-720.
26. Raff GL, Glantz SA. Volume loading slows left ventricular isovolumic relaxation rate. Evidence of load-dependent relaxation in the intact dog heart. Circ Res 1981;48:813-824.
27. Wheeler MT, Korcarz CE, Collins KA, Lapidos KA, Hack AA, Lyons MR et al. Secondary coronary artery vasospasm promotes cardiomyopathy progression. Am J Pathol 2004;164:1063-1071.
28. Silver HM, Seebeck M, Carlson R. Comparison of total blood volume in normal, preeclamptic, and nonproteinuric gestational hypertensive pregnancy by simultaneous measurement of red blood cell and plasma volumes. Am Obstet Gynecol 1998;179:87-93.
29. Porreca E, Guglielmi MD, Uncini A, Di Gregorio P, Angelini A, Di Febbo C et al. Haemostatic abnormalities cardiac involvement and serum tumor necrosis factor levels in X-linked dystrophic patients. Thromb Haemost 1999;81:543-546.
30. Paulus WJ. Cytokines and heart failure. Heart Fail Monit 2000;1:50-56.
31. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997;79:1128- 1131.
32. Hamer PW, McGeachie JM, Davies MJ, Grounds MD. Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability. J Anat 2002;200:69-79.
33. Ruegg UT, Nicolas-Metral V, Challet C, Bernard-Helary K, Dorchies OM, Wagner S et al. Pharmacological control of cellular calcium handling in dystrophic skeletal muscle. Neuromuscul Disord 2002;12(Suppl. 1):S155-S161.
34. Kurrelmeyer KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, Sivasubramanian N et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA 2000;97:5456- 5461.
35. Sack MN, Smith RM, Opie LH. Tumor necrosis factor in myocardial hypertrophy and ischaemia - an anti-apoptotic perspective. Cardiovasc Res 2000;45:688-695.
36. Mann DL, McMurray JJV, Packer M, Swedberg K, Borer JS, Colucci WS et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-1602.
37. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007;115:1754- 1761.
38. Connolly AM, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002;12:917-925.
39. Fenichel GM, Florence JM, Pestronk A, Mendell JR, Moxley RT, Griggs RC et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991;41:1874-1877.
40. Weller B, Massa R, Karpati G, Carpenter S. Glucocorticoids and immunosuppressants do not change the prevalence of necrosis and regeneration in mdx skeletal muscles. Muscle Nerve 1991;14:771-774.